{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:40:46Z","timestamp":1785796846226,"version":"3.56.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Liver cancer is largely resistant to chemotherapy. This study aimed to identify the effective chemotherapeutics for \u03b2-catenin-activated liver cancer which is caused by gain-of-function mutation of catenin beta 1 (<jats:italic toggle=\"yes\">CTNNB1<\/jats:italic>), the most frequently altered proto-oncogene in hepatic neoplasms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Constitutive \u03b2-catenin-activated mouse embryonic fibroblasts (MEFs) were established by deleting exon 3 (<jats:italic toggle=\"yes\">\u03b2-catenin\u0394(ex3)\/+\n                                 <\/jats:italic>), the most common mutation site in <jats:italic toggle=\"yes\">CTNNB1<\/jats:italic> gene. A screening of 12 widely used chemotherapy drugs was conducted for the ones that selectively inhibited <jats:italic toggle=\"yes\">\u03b2-catenin\u0394(ex3)\/+\n                                 <\/jats:italic> but not for wild-type MEFs. Untargeted metabolomics was carried out to examine the alterations of metabolites in nucleotide synthesis. The efficacy and selectivity of methotrexate (MTX) on \u03b2-catenin-activated human liver cancer cells were determined <jats:italic toggle=\"yes\">in vitro<\/jats:italic>. Immuno-deficient nude mice subcutaneously inoculated with \u03b2-catenin wild-type or mutant liver cancer cells and hepatitis B virus (<jats:italic toggle=\"yes\">HBV<\/jats:italic>); <jats:italic toggle=\"yes\">\u03b2-cateninlox(ex3)\/+\n                                 <\/jats:italic> mice were used, respectively, to evaluate the efficacy of MTX in the treatment of \u03b2-catenin mutant liver cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>MTX was identified and validated as a preferential agent against the proliferation and tumor formation of \u03b2-catenin-activated cells. Boosted nucleotide synthesis was the major metabolic aberration in \u03b2-catenin-active cells, and this alteration was also the target of MTX. Moreover, MTX abrogated hepatocarcinogenesis of <jats:italic toggle=\"yes\">HBV<\/jats:italic>; <jats:italic toggle=\"yes\">\u03b2-cateninlox(ex3)\/+\n                                 <\/jats:italic> mice, which stimulated concurrent <jats:italic toggle=\"yes\">Ctnnb1-<\/jats:italic>activated mutation and HBV infection in liver cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>MTX is a promising chemotherapeutic agent for \u03b2-catenin hyperactive liver cancer. Since repurposing MTX has the advantages of lower risk, shorter timelines, and less investment in drug discovery and development, a clinical trial is warranted to test its efficacy in the treatment of \u03b2-catenin mutant liver cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002816","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T03:00:11Z","timestamp":1692846011000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Oncogenic \u03b2-catenin-driven liver cancer is susceptible to methotrexate-mediated disruption of nucleotide synthesis"],"prefix":"10.1097","volume":"137","author":[{"given":"Fangming","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China"},{"name":"Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Physiology, School of Life Science, China Medical University, Shenyang, Liaoning 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhuo","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengju","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Pediatric Hematology and Oncology, Ministry of Health, Institute of Pediatric Translational Medicine, Shanghai Children's Medical Center, Shanghai Jiao Tong School of Medicine, Shanghai 200127, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Gai","sequence":"additional","affiliation":[{"name":"Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Physiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"R1-20241227","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing pro\ufb01les of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J"},{"key":"R2-20241227","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20241227","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R4-20241227","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R5-20241227","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jhep.2014.08.009","article-title":"The genomic landscape of hepatoblastoma and their progenies with HCC-like features","volume":"61","author":"Eichenm\u00fcller","year":"2014","journal-title":"J Hepatol"},{"key":"R6-20241227","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/hep.28638","article-title":"Genotype-phenotype correlation of CTNNB1 mutations reveals different \u03b2-catenin activity associated with liver tumor progression","volume":"64","author":"Rebouissou","year":"2016","journal-title":"Hepatology"},{"key":"R7-20241227","first-page":"1971","article-title":"Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin","volume":"62","author":"Harada","year":"2002","journal-title":"Cancer Res"},{"key":"R8-20241227","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"key":"R9-20241227","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cell.2019.10.038","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"key":"R10-20241227","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202157119","article-title":"Oncogenic beta-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer","volume":"119","author":"Liu","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"R11-20241227","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jhep.2022.02.023","article-title":"Deleting the beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth","volume":"77","author":"Loesch","year":"2022","journal-title":"J Hepatol"},{"key":"R12-20241227","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/18884","article-title":"Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells","volume":"398","author":"Tetsu","year":"1999","journal-title":"Nature"},{"key":"R13-20241227","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.devcel.2011.04.010","article-title":"Beta-catenin-dependent FGF signaling sustains cell survival in the anterior embryonic head by countering Smad4","volume":"20","author":"Paek","year":"2011","journal-title":"Dev Cell"},{"key":"R14-20241227","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.21131","article-title":"Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice","volume":"43","author":"Sekine","year":"2006","journal-title":"Hepatology"},{"key":"R15-20241227","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/gutjnl-2017-315448","article-title":"beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids","volume":"68","author":"Senni","year":"2019","journal-title":"Gut"},{"key":"R16-20241227","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1126\/science.1218370","article-title":"Wnt\/beta-catenin signaling regulates telomerase in stem cells and cancer cells","volume":"336","author":"Hoffmeyer","year":"2012","journal-title":"Science"},{"key":"R17-20241227","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12967-023-03914-0","article-title":"Beta-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active beta-catenin-mediated cancer","volume":"21","author":"Wu","year":"2023","journal-title":"J Transl Med"},{"key":"R18-20241227","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/beta-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"R19-20241227","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R20-20241227","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12967-023-03914-0","article-title":"beta-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active beta-catenin-mediated cancer","volume":"21","author":"Wu","year":"2023","journal-title":"J Transl Med"},{"key":"R21-20241227","first-page":"100032","article-title":"Therapy of primary liver cancer","volume":"1","author":"Feng","year":"2020","journal-title":"Innovation"},{"key":"R22-20241227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","article-title":"One-carbon metabolism in health and disease","volume":"25","author":"Ducker","year":"2017","journal-title":"Cell Metab"},{"key":"R23-20241227","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/2159-8290.CD-16-0612","article-title":"PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition","volume":"7","author":"Mathur","year":"2017","journal-title":"Cancer Discov"},{"key":"R24-20241227","article-title":"p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage","volume":"118","author":"Li","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-20241227","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nature22359","article-title":"CPS1 maintains pyrimidine pools and DNA synthesis in KRAS\/LKB1-mutant lung cancer cells","volume":"546","author":"Kim","year":"2017","journal-title":"Nature"},{"key":"R26-20241227","doi-asserted-by":"crossref","first-page":"11049","DOI":"10.1007\/s11033-022-07782-7","article-title":"A comprehensive review on methotrexate containing nanoparticles; an appropriate tool for cancer treatment","volume":"49","author":"Shariatifar","year":"2022","journal-title":"Mol Biol Rep"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T22:02:44Z","timestamp":1735336964000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002816","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"2023-04-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}